Association of the TNFRSF1A genotype with lung function impairment in patients with sarcoidosis.

A G Lunde, S Romundstad, A H Henriksen, H Sorger, E Boerner, N Schröder, F Bonella

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

A G LundeDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. astrigl@stud.ntnu.no.

S RomundstadDepartment of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

A H HenriksenClinic of Medicine, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.

H SorgerLevanger Hospital, Nord-Trondelag Hospital Trust - Levanger, Levanger, Norway.

E BoernerCenter for Interstitial and Rare Lung Diseases, Pulmonology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany.

N SchröderCenter for Interstitial and Rare Lung Diseases, Pulmonology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany.

F BonellaCenter for Interstitial and Rare Lung Diseases, Pulmonology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The single-nucleotide polymorphism (SNP) rs1800693 in the tumor necrosis factor receptor 1 (TNFR1) gene leads to the formation of a protein-mimicking effect of TNF-α inhibitors, which are agents used to treat sarcoidosis. We investigated the association between rs1800693 and disease progression in two populations with non-Lofgren sarcoidosis (nLS). We genotyped two nLS cohorts (Ruhrlandklinik, Germany, n = 108, and the HUNT study, Norway, n = 393), and two control groups with (n = 313) and without (n = 2414) COPD for rs1800693 (A/G polymorphism). Pulmonary function tests at inclusion and at the end of follow-up were compared according to genotype. The mean follow-up times were 6.5 (German) and 7.9 (Norwegian) years. German AA patients had an absolute decline in %pred FVC (-8.5, 95% CI -3.4, -13.6) and DLco (-4.9, 95% CI -0.1, -9.7). In AG/GG (G+), the absolute decline in FVC was less pronounced (-3.9, 95% CI -1.1, -6.8), and DLco was stable. In the Norwegian patients, the decrease in lung function was similar between the AA and G+ groups. Compared with homozygous GG, homozygous AA was associated with a lower FVC %pred at baseline (-5.7, 95% CI -0.2, -11.6) and at the end of follow-up (-7.0, 95% CI -0.1, -14.0). Genotype was not associated with lung function in either control group. TNFR1 rs1800693 might be associated with lung function impairment and decline in non-Lofgren sarcoidosis patients.

Indexed as

LungPolymorphism, Single NucleotideReceptors, Tumor Necrosis Factor, Type ISarcoidosisAdultDisease ProgressionFemaleGenetic Association StudiesGenetic Predisposition to DiseaseGenotypeGermanyHumansMaleMiddle AgedNorwayRespiratory Function TestsReceptors, Tumor Necrosis Factor, Type ITNFRSF1A protein, humanLung functionPrognosisrs1800693SarcoidosisTNFR1TNF-α

Identifiers

PMID42086639

DOI10.1038/s41598-026-51077-x

PMCPMC13333820

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.